We are re-evaluating our processes around Closed System Drug-Transfer Devices (CSTD). I am curious to hear of other institutional approaches to non-IV routes:
Do you use the same CSTD system across your enterprise for consistency, or a different one to distinguish?
In particular I am thinking of intravesicular, intramuscular, and/or Subcutaneous routes.